VEGFA and diffuse large B-cell lymphoma: Bevacizumab, a 93% humanized IgG1 anti-VEGF monoclonal antibody, has been tested both as a single agent (SWOG 0108 study)[10,11] and in combination with chemotherapy (SWOG0515 study)[12] in DLBCL patients.